Equillium receives Nasdaq bid price deficiency notice; cure deadline Jan 15, 2025

Equillium, Inc.

Received Nasdaq notice on July 19, 2024 for bid price below $1.00 for 30 consecutive business days.
Has 180-day grace period until Jan 15, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.
If not cured, may qualify for additional 180-day period if meeting other initial listing standards.
Company will consider options including a reverse stock split to cure the bid price deficiency.
Common stock continues to trade on Nasdaq Capital Market under symbol 'EQ' with no immediate effect.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.